National and Transnational Security Implications of Asymmetric Access to and Use of Biological Data

Biology and biotechnology have changed dramatically during the past 20 years, in part because of increases in computational capabilities and use of engineering principles to study biology. The advances in supercomputing, data storage capacity, and cloud platforms enable scientists throughout the world to generate, analyze, share, and store vast amounts of data, some of which are biological and much of which may be used to understand the human condition, agricultural systems, evolution, and environmental ecosystems. These advances and applications have enabled: (1) the emergence of data science, which involves the development of new algorithms to analyze and visualize data; and (2) the use of engineering approaches to manipulate or create new biological organisms that have specific functions, such as production of industrial chemical precursors and development of environmental bio-based sensors. Several biological sciences fields harness the capabilities of computer, data, and engineering sciences, including synthetic biology, precision medicine, precision agriculture, and systems biology. These advances and applications are not limited to one country. This capability has economic and physical consequences, but is vulnerable to unauthorized intervention. Healthcare and genomic information of patients, information about pharmaceutical and biotechnology products in development, and results of scientific research have been stolen by state and non-state actors through infiltration of databases and computer systems containing this information. Countries have developed their own policies for governing data generation, access, and sharing with foreign entities, resulting in asymmetry of data sharing. This paper describes security implications of asymmetric access to and use of biological data

Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update

To report long-term results for children with low-grade hypothalamic/chiasmatic gliomas treated on a phase II chemotherapy protocol. Between 1984 and 1992, 33 children with hypothalamic/chiasmatic LGGs received TPDCV chemotherapy on a phase II prospective trial. Median age was 3.0 years (range 0.3–16.2). Twelve patients (36%) underwent STRs, 14 (42%) biopsy only, and seven (21%) no surgery. Twenty patients (61%) had pathologic JPAs, nine (27%) grade II gliomas, and four (12%) no surgical sampling. Median f/u for surviving patients was 15.2 years (range 5.3–20.7); 20 of the 23 surviving patients had 14 or more years of follow-up. Fifteen-year PFS and OS were 23.4 and 71.2%, respectively. Twenty-five patients progressed, of whom 13 are NED, two are AWD, and 10 have died. All children who died were diagnosed and first treated at age three or younger. Age at diagnosis was significantly associated with relapse and survival (P = 0.004 for PFS and P = 0.037 for OS). No PFS or OS benefit was seen with STR versus biopsy/no sampling (P = 0.58 for PFS, P = 0.59 for OS). For patients with JPAs and WHO grade II tumors, the 15-year PFS was 18.8 and 22.2% (P = 0.95) and 15-year OS was 73.7 and 55.6% (P = 0.17), respectively. Upfront TPDCV for children with hypothalamic/chiasmatic LGGs resulted in 15-year OS of 71.2% and 15-year PFS of 23.4%. No survival benefit is demonstrated for greater extent of resection. Age is a significant prognostic factor for progression and survival

Role of Collectins and Complement Protein C1q in pregnancy and parturition

Collectins such as surfactant proteins SP-A, SP-D, and mannan-binding lectin (MBL), as well as complement protein C1q are evolutionarily conserved innate immune molecules. They are known to opsonize a range of microbial pathogens (bacteria, fungi, virus, and parasites) and trigger effector clearance mechanisms involving phagocytosis and/or complement activation. Collectins and C1q have also attracted attention in studies involving pregnancy as they are expressed in the female reproductive tissues during pregnancy; a unique state of immune suppression with increased susceptibility to infectious diseases. Recent studies are beginning to unravel their functional significance in implantation, placentation, pregnancy maintenance and parturition in normal and adverse pregnancies. Collectins and C1q, expressed in gestational tissues during pregnancy, might alter the status of mother’s immune response to the allogenic fetus and the microenvironment, thereby serving as important regulators of fetus-mother interaction. Here, we discuss the functional roles that have been assigned to SPA, SP-D, MBL and C1q in pregnancy and parturition

Future opportunities for bioengagement in the MENA region

The American Association for the Advancement of Science (AAAS) Center for Science, Technology, and Security Policy (CSTSP) received a grant from the Naval Postgraduate School, a part of the Department of Defense, to identify new opportunities and approaches for future bioengagement in the MENA region based on regional consultations with scientific and health experts. AAAS held regional consultations in Morocco (with North African participants) and Jordan (with Middle East participants) wherein regional and U.S. experts discussed gaps in bioengagement, suggested opportunities for future engagement, and explored metrics of effectiveness and long term impact of bioengagement efforts. To facilitate these discussions, AAAS suppported a collaborative grant that evaluated the impact of regional laboratory biosafety and biosecurity efforts, and commissioned two papers to identify lessons learned from past and current regional efforts and suggest new approaches for future bioengagement. The collaborative grant and commissioned papers were discussed and/or presented in Morocco and Jordan. During the implementation of AAAS's project, the Middle East Respiratory Syndrome (MERS) coronavirus emerged in Saudi Arabia, Somalia saw its first case of polio since the 1970s, H7N9 influenza emerged in Southeast Asia. Syrian refugees entered Jordan and other neighboring coutries bringing unknown infections, and chemical weapons were used on Syrian citizens. Scientific and health experts from MENA countries expressed concern about these occurrences and identified opportunities for engagement that minimized these and other socio-political concerns. AAAS carried out this project as DTRA explored cooperative bioengagement in MENA countries and as the U.S. Congress wrote and introduced a bill on cooperative threat reduction in the Middle East and North Africa. These policy and programmatic developments officed a unique opportunity to provide regional input in U.S.-MENA cooperative bioengagement.PASCC Grant no. N00244-12-1-0039. PASCC is supported by the Defense Threat Reduction Agency (DTRA)